MOB015B

DRUG7 trials

Sponsors

Moberg Pharma AB

Conditions

Distal Subungual OnychomycosisErythemaOnychomycosis

Phase 1

A Study of the Systemic Absorption of MOB015B

CompletedNCT03244280

Moberg Pharma ABOnychomycosis

Start: 2017-12-16End: 2018-04-23Updated: 2018-05-03

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

CompletedNCT06369727

Moberg Pharma ABErythema

Start: 2017-10-15End: 2018-02-15Updated: 2024-04-17

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

CompletedNCT06369675

Moberg Pharma ABErythema

Start: 2017-10-19End: 2017-11-14Updated: 2024-04-17

Phase 2

An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

CompletedNCT01814020

Moberg Pharma ABDistal Subungual Onychomycosis

Start: 2012-12-31End: 2014-07-31Updated: 2014-09-22

Phase 3

A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

CompletedNCT02859519

Moberg Pharma ABDistal Subungual Onychomycosis

Start: 2016-10-31End: 2019-11-13Updated: 2020-12-24

Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

CompletedNCT02866032

Moberg Pharma ABDistal Subungual Onychomycosis

Start: 2016-09-30End: 2020-06-10Updated: 2020-10-06

A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

Active, not recruitingNCT05279846

Moberg Pharma ABOnychomycosis

Start: 2022-05-09End: 2025-01-31Target: 350Updated: 2024-06-26

Related Papers

Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis

Antimicrobial Agents and Chemotherapy2024-08-193 citations